Antengene Dirección

Dirección controles de criterios 2/4

Antengene's CEO is Jay Mei, appointed in Aug 2020, has a tenure of 4.25 years. total yearly compensation is CN¥16.77M, comprised of 37.8% salary and 62.2% bonuses, including company stock and options. directly owns 26% of the company’s shares, worth HK$148.41M. The average tenure of the management team and the board of directors is 4.3 years and 4 years respectively.

Información clave

Jay Mei

Chief Executive Officer (CEO)

CN¥16.8m

Compensación total

Porcentaje del salario del CEO	37.8%
Permanencia del CEO	4.3yrs
Participación del CEO	26.0%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Mei en comparación con los beneficios de Antengene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥530m
Mar 31 2024	n/a	n/a	-CN¥555m
Dec 31 2023	CN¥17m	CN¥6m	-CN¥581m
Sep 30 2023	n/a	n/a	-CN¥628m
Jun 30 2023	n/a	n/a	-CN¥676m
Mar 31 2023	n/a	n/a	-CN¥639m
Dec 31 2022	CN¥15m	CN¥6m	-CN¥601m
Sep 30 2022	n/a	n/a	-CN¥584m
Jun 30 2022	n/a	n/a	-CN¥567m
Mar 31 2022	n/a	n/a	-CN¥611m
Dec 31 2021	CN¥17m	CN¥5m	-CN¥656m

Compensación vs. Mercado: Jay's total compensation ($USD2.37M) is above average for companies of similar size in the Hong Kong market ($USD234.60K).

Compensación vs. Ingresos: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Mei (59 yo)

4.3yrs

Permanencia

CN¥16,774,000

Compensación

Dr. Jay Mei, M.D. & Ph.D. is the Founder of Antengene Corporation and serves as Chairman and Chief Executive Officer since August 18, 2020. Dr. Mei has experience in clinical research and development of on...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Mei	Founder	4.3yrs	CN¥16.77m	26% HK$ 148.4m
Donald Andrew Lung	CFO & Executive Director	4.4yrs	CN¥7.12m	sin datos
John F. Chin	Executive Director & Chief Business Officer	no data	CN¥5.96m	0.020% HK$ 113.8k
Eitan Liu	Chief Operating Officer	4.3yrs	sin datos	sin datos
Shimin Sun	Corporate VP and Head of Clinical Enabling Functions & Operational Excellence	no data	sin datos	sin datos
Thomas Karalis	Corporate VP & Head of Asia Pacific Region	4.6yrs	sin datos	sin datos
Dirk Hoenemann	VP and Head of Medical Affairs for APAC & Early Clinical Development	4.3yrs	sin datos	sin datos
Xiaojing Zhang	Chief Medical Officer	1.9yrs	sin datos	sin datos
Yang Cao	Joint Company Secretary	no data	sin datos	sin datos
Wai Chiu Wong	Joint Company Secretary	2.7yrs	sin datos	sin datos

4.3yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: 6996's management team is considered experienced (4.3 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Mei	Founder	6.3yrs	CN¥16.77m	26% HK$ 148.4m
Donald Andrew Lung	CFO & Executive Director	3.4yrs	CN¥7.12m	sin datos
John F. Chin	Executive Director & Chief Business Officer	4.3yrs	CN¥5.96m	0.020% HK$ 113.8k
Timothy M. Block	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joseph Camardo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Shaji K. Kumar	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Barrett	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Gale	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jing Qian	Independent Non-Executive Director	4yrs	CN¥487.00k	sin datos
Sheng Tang	Independent Non-Executive Director	4yrs	CN¥487.00k	sin datos
Rafael Fonseca	Independent Non-Executive Director	1.6yrs	CN¥193.00k	sin datos
Florence Houn	Member of the Scientific Advisory Board	no data	sin datos	sin datos

4.0yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: 6996's board of directors are considered experienced (4 years average tenure).

Antengene Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Antengene Corporation Limited Announces Management Changes

Recent updates

South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO

First half 2024 earnings: EPS and revenues exceed analyst expectations

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

New minor risk - Share price stability

Consensus revenue estimates decrease by 32%, EPS upgraded

First half 2024 earnings: EPS and revenues exceed analyst expectations

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

New minor risk - Share price stability

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Antengene Corporation Limited Announces Executive Changes

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Less than half of directors are independent

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Less than half of directors are independent

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth